Status:
UNKNOWN
Ropivacaine Use in Interscalene Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)
Lead Sponsor:
Healthpoint Hospital
Conditions:
Postoperative Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study aim to calculate the minimal effective ropivacaine concentration required achieve successful analgesic interscalene block in 90% of patients (MEAC90)
Detailed Description
* Before induction of general anesthesia, all patients will receive interscalene block using 15ml of ropivacaine which concentration will be based on the response of the previous patient. * Based on b...
Eligibility Criteria
Inclusion
- Patients, who are scheduled for shoulder arthroscopy
Exclusion
- \- \<18 y,
- ASA physical class greater \>III
- BMI \>40 has any contraindication for medications or techniques used in the study
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2021
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04833296
Start Date
May 1 2021
End Date
September 30 2021
Last Update
April 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Healthpoint Hospital
Abu Dhabi, United Arab Emirates, 112308